Filtern
Volltext vorhanden
- ja (37)
Gehört zur Bibliographie
- ja (37)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (37)
Schlagworte
- osteoporosis (4)
- hypophosphatasia (3)
- mechanotransduction (3)
- mineralization (3)
- sarcopenia (3)
- HPP (2)
- LMHFV (2)
- Mesenchymal stem cells (2)
- Multiple myeloma (2)
- TNAP (2)
- back pain (2)
- bone-mineral density (2)
- differentiation (2)
- exercise (2)
- fracture (2)
- fracture healing (2)
- in-vitro (2)
- inflammation (2)
- model (2)
- nervous system (2)
- oestrogen receptor signalling (2)
- stromal cells (2)
- teriparatide (2)
- 2',7'-dichlorofluorescin (1)
- 3D printing (1)
- ALPL (1)
- Angiopoietin-like 4 (1)
- Bioreaktor (1)
- Bisphosphonates (1)
- Bone Mineral Density (1)
- Bone disease (1)
- Breast cancer cells (1)
- CCN1 (1)
- Caspase 3/7 activity (1)
- Cell viability, (1)
- EQ-5D (1)
- ER signaling (1)
- Endothelial growth-factor (1)
- Gene expression profiling (1)
- Hypophosphatasia (1)
- Mechanical strain (1)
- Medizin (1)
- Novobiocin (1)
- Osteogenic precursor cells (1)
- Probenecid (1)
- RT-PCR (1)
- Splicing (1)
- WNT pathway (1)
- WNT signaling pathway (1)
- WNT5A (1)
- Wnt (1)
- Wnt signalling (1)
- Wnt-signalling (1)
- Wnt/β-catenin signaling (1)
- additive manufacturing (1)
- age (1)
- age-related osteoporosis (1)
- aging (1)
- alendronate (1)
- alkaline phosphatase (1)
- alkaline-phosphatase (1)
- alpha (1)
- angiogenic cytokines (1)
- aseptic loosening (1)
- asfotase alfa (1)
- autologous chondrocyte implantation (1)
- autosomal-dominant osteopetrosis (1)
- biceps tendon (1)
- biodegradable polymers (1)
- biomarkers Myelomas (1)
- bioreactor (1)
- bisphosphonates (1)
- bone (1)
- bone QCT (1)
- bone biology (1)
- bone formation (1)
- bone imaging (1)
- bone marrow (1)
- bone marrow lesion/edema (1)
- bone marrow stromal cells (1)
- bone mineral density (1)
- bone remodeling (1)
- bone tumour (1)
- cancer microenvironment (1)
- cardiovascular (1)
- cells (1)
- cellular signalling networks (1)
- click chemistry (1)
- colony-stimulating factor (1)
- community-dwelling (1)
- computer modelling (1)
- core depression (1)
- craniosynostosis (1)
- database (1)
- early stage (1)
- epidermal growth factor (1)
- expression (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- gene (1)
- gene constructs (1)
- gene-expression (1)
- glycocalyx (1)
- growth factor (1)
- hMSC-TERT (1)
- health-related quality of life (1)
- high-bone-mass (1)
- homeostasis (1)
- human atherosclerotic lesions (1)
- hypovitaminosis D (1)
- impact (1)
- in situ guided tissue regeneration (1)
- in situ hybridization (1)
- in vitro (1)
- level mechanical vibrations (1)
- lines (1)
- malignancy (1)
- marrow stromal cells (1)
- mechanosensing (1)
- mechanosensitive reporter (1)
- men (1)
- mesenchymal cells (1)
- mesenchymal stem cell (1)
- mesenchymal stem cells (1)
- mesenchymal stem-cells (1)
- mesenchymal stromal cells (1)
- mesenchymal tissues (1)
- metaanalysis (1)
- metabolic glycoengineering (1)
- metabolic risk (1)
- metabolic syndrome (1)
- metabolism (1)
- microstructures (1)
- mineraliztion (1)
- modified monosaccharides (1)
- monoclonial gammopathy (1)
- morphogenetic protein (1)
- multiple myeloma Lesions (1)
- muscle (1)
- mutant mice (1)
- mutations (1)
- myeloma (1)
- myeloma cells (1)
- myokines (1)
- nanostructures (1)
- neurotransmission (1)
- nonspecific alkaline-phosphae (1)
- obesity (1)
- older people (1)
- osteoblastic cells (1)
- osteochondral allografts (1)
- osteoclasts (1)
- osteogenesis imperfecta (1)
- osteogenic differentiation (1)
- osteokines adaptation (1)
- osteomalacia (1)
- osteopenia (1)
- ovariectomized rats (1)
- ovariectomy (1)
- overview (1)
- oxidative stress (1)
- parathyroid-hormone (1)
- peripheral-blood (1)
- persistence (1)
- perspectives (1)
- precedes multiple-myeloma (1)
- prevalent fractures (1)
- progenitor cells (1)
- proliferation (1)
- promotes (1)
- quality of life (1)
- rare bone disease (1)
- receptor beta (1)
- receptor related protein (1)
- regenerative capacity (1)
- regenerative medicine (1)
- replacement therapy (1)
- replicative senescence (1)
- resistance exercise (1)
- responsiveness (1)
- rickets (1)
- scaffolds (1)
- segmental collapse (1)
- senescence (1)
- senescence‐associated secretory phenotype (1)
- serum amyloid A (1)
- sheep model (1)
- shoulder (1)
- signaling (1)
- skeletal overexpression (1)
- stem cells (1)
- teeth (1)
- tendon-derived stem cell (1)
- tissue (1)
- tissue engineering (1)
- toll-like receptor (1)
- transcription factors (1)
- tumour malignancy (1)
- undetermined significance (1)
- vertebral fractures (1)
- vertebrate (1)
- vitamin D (1)
- vitamin D deficiency (1)
- vitamin-D-receptor (1)
- whole body vibration (1)
- whole-body electromyostimulation (1)
- whole-body vibration (1)
- zebrafish (1)
- zoledronic acid (1)
Institut
- Lehrstuhl für Orthopädie (37)
- Medizinische Klinik und Poliklinik II (4)
- Institut für Humangenetik (3)
- Kinderklinik und Poliklinik (3)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (3)
- Theodor-Boveri-Institut für Biowissenschaften (3)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
- Fakultät für Mathematik und Informatik (1)
- Institut für Molekulare Infektionsbiologie (1)
EU-Projektnummer / Contract (GA) number
- 241719 (1)
- 242175 (1)
- 617989 (1)
- EU-1650-0006 (1)
Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head
(2012)
Avascular necrosis (AVN) of the femoral head is a debilitating disease of multifactorial genesis, predominately affects young patients, and often leads to the development of secondary osteoarthritis. The evolving field of regenerative medicine offers promising treatment strategies using cells, biomaterial scaffolds, and bioactive factors, which might improve clinical outcome. Early stages of AVN with preserved structural integrity of the subchondral plate are accessible to retrograde surgical procedures, such as core decompression to reduce the intraosseous pressure and to induce bone remodeling. The additive application of concentrated bone marrow aspirates, ex vivo expanded mesenchymal stem cells, and osteogenic or angiogenic growth factors (or both) holds great potential to improve bone regeneration. In contrast, advanced stages of AVN with collapsed subchondral bone require an osteochondral reconstruction to preserve the physiological joint function. Analogously to strategies for osteochondral reconstruction in the knee, anterograde surgical techniques, such as osteochondral transplantation (mosaicplasty), matrix-based autologous chondrocyte implantation, or the use of acellular scaffolds alone, might preserve joint function and reduce the need for hip replacement. This review summarizes recent experimental accomplishments and initial clinical findings in the field of regenerative medicine which apply cells, growth factors, and matrices to address the clinical problem of AVN.
Hypophosphatasia (HPP) is a rare genetic disease with diverse symptoms and a heterogeneous severity of onset with underlying mutations in the ALPL gene encoding the ectoenzyme Tissue-nonspecific alkaline phosphatase (TNAP). Considering the establishment of zebrafish (Danio rerio) as a new model organism for HPP, the aim of the study was the spatial and temporal analysis of alpl expression in embryos and adult brains. Additionally, we determined functional consequences of Tnap inhibition on neural and skeletal development in zebrafish. We show that expression of alpl is present during embryonic stages and in adult neuronal tissues. Analyses of enzyme function reveal zones of pronounced Tnap-activity within the telencephalon and the mesencephalon. Treatment of zebrafish embryos with chemical Tnap inhibitors followed by axonal and cartilage/mineralized tissue staining imply functional consequences of Tnap deficiency on neuronal and skeletal development. Based on the results from neuronal and skeletal tissue analyses, which demonstrate an evolutionary conserved role of this enzyme, we consider zebrafish as a promising species for modeling HPP in order to discover new potential therapy strategies in the long-term.
Epidermal growth factors (EGFs) e.g. EGF, heparin-binding EGF and transforming growth factor alpha and their receptors e.g. EGFR and ErbB2 control proinflammatory signaling and modulate proliferation in bone marrow stromal cells (BMSC). Interleukin-6 and interleukin-8 are EGF targets and participate in the inflammatory phase of bone regeneration via non-canonical wnt signaling. BMSC differentiation is also influenced by mechanical strain-related activation of ERK1/2 and AP-1, but the role of EGFR signaling in mechanotransduction is unclear. We investigated the effects of EGFR signaling in telomerase-immortalized BMSC, transfected with a luciferase reporter, comprising a mechanoresponsive AP1 element, using ligands, neutralizing antibodies and EGFR inhibitors on mechanotransduction and we found that EGF via EGFR increased the response to mechanical strain. Results were confirmed by qPCR analysis of mechanoresponsive genes. EGF-responsive interleukin-6 and interleukin-8 were synergistically enhanced by EGF stimulation and mechanical strain. We show here in immortalized and primary BMSC that EGFR signaling enhances mechanotransduction, indicating that the EGF system is a mechanosensitizer in BMSC. Alterations in mechanosensitivity and -adaptation are contributors to age-related diseases like osteoporosis and the identification of a suitable mechanosensitizer could be beneficial. The role of the synergism of these signaling cascades in physiology and disease remains to be unraveled.
In contrast to postmenopausal women, evidence for a favorable effect of exercise on Bone Mineral Density (BMD) is still limited for men. This might be due to the paucity of studies, but also to the great variety of participants and study characteristics that may dilute study results. The aim of the present systematic review and meta-analysis was to evaluate the effect of exercise on BMD changes with rational eligibility criteria. A comprehensive search of six electronic databases up to 15 March 2021 was conducted. Briefly, controlled trials ≥6 months that determined changes in areal BMD in men >18 years old, with no apparent diseases or pharmacological therapy that relevantly affect bone metabolism, were included. BMD changes (standardized mean differences: SMD) of the lumbar spine (LS) and femoral neck (FN) were considered as outcomes. Twelve studies with 16 exercise and 12 control groups were identified. The pooled estimate of random-effect analysis was SMD = 0.38, 95%-CI: 0.14–0.61 and SMD = 0.25, 95%-CI: 0.00–0.49, for LS and FN, respectively. Heterogeneity between the trials was low–moderate. Funnel plots and rank and regression correlation tests indicate evidence for small study publication bias for LS but not FN-BMD. Subgroup analyses that focus on study length, type of exercise and methodologic quality revealed no significant difference between each of the three categories. In summary, we provided further evidence for a low but significant effect of exercise on BMD in men. However, we are currently unable to give even rough exercise recommendations for male cohorts.
Background: To describe changes in health-related quality of life (HRQoL) of postmenopausal women with osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess the influence of recent prior and incident fractures.
Methods: The European Forsteo Observational Study (EFOS) is an observational, prospective, multinational study measuring HRQoL using the EQ-5D. The primary objective was to assess changes in HRQoL during 36 months in the whole study population. A secondary post-hoc analysis examined fracture impact on HRQoL in four subgroups classified based on recent prior fracture 12 months before baseline and incident clinical fractures during the study. Changes from baseline were analysed using a repeated measures model.
Results: Of the 1581 patients, 48.4% had a recent prior fracture and 15.6% of these patients had an incident fracture during follow-up. 10.9% of the 816 patients with no recent prior fracture had an incident fracture. Baseline mean EQ-VAS scores were similar across the subgroups. In the total study cohort (n = 1581), HRQoL (EQ-VAS and EQ-5D index scores) improved significantly from baseline to 18 months and this improvement was maintained over the 18-month post-teriparatide period. Improvements were seen across all five EQ-5D domains during teriparatide treatment that were maintained after teriparatide was discontinued. Subjects with incident clinical fractures had significantly less improvement in EQ-VAS than those without incident fractures. Recent prior fracture did not influence the change in EQ-VAS during treatment.
Conclusions: EFOS is the first longitudinal study in women with severe postmenopausal osteoporosis in the real world setting to show a substantial improvement in HRQoL during teriparatide treatment that was sustained during subsequent treatment with other medications. The increase in HRQoL was lower in the subgroups with incident fracture but was not influenced by recent prior fracture. The results should be interpreted in the context of the design of an observational study.
Tissue-nonspecific alkaline phosphatase (TNAP) is a ubiquitously expressed enzyme that is best known for its role during mineralization processes in bones and skeleton. The enzyme metabolizes phosphate compounds like inorganic pyrophosphate and pyridoxal-5′-phosphate to provide, among others, inorganic phosphate for the mineralization and transportable vitamin B6 molecules. Patients with inherited loss of function mutations in the ALPL gene and consequently altered TNAP activity are suffering from the rare metabolic disease hypophosphatasia (HPP). This systemic disease is mainly characterized by impaired bone and dental mineralization but may also be accompanied by neurological symptoms, like anxiety disorders, seizures, and depression. HPP characteristically affects all ages and shows a wide range of clinical symptoms and disease severity, which results in the classification into different clinical subtypes. This review describes the molecular function of TNAP during the mineralization of bones and teeth, further discusses the current knowledge on the enzyme’s role in the nervous system and in sensory perception. An additional focus is set on the molecular role of TNAP in health and on functional observations reported in common laboratory vertebrate disease models, like rodents and zebrafish.
The canonical Wnt/beta-catenin pathway plays a key role in the regulation of bone remodeling in mice and humans. Two transmembrane proteins that are involved in decreasing the activity of this pathway by binding to extracellular antagonists, such as Dickkopf 1 (Dkk1), are the low-density lipoprotein receptor related protein 5 (Lrp5) and Kremen 2 (Krm2). Lrp 5 deficiency (Lrp5(-/-)) as well as osteoblast-specific overexpression of Krm2 in mice (Col1a1-Krm2) result in severe osteoporosis occurring at young age. In this study, we analyzed the influence of Lrp5 deficiency and osteoblast-specific overexpression of Krm2 on fracture healing in mice using flexible and semi-rigid fracture fixation. We demonstrated that fracture healing was highly impaired in both mouse genotypes, but that impairment was more severe in Col1a1-Krm2 than in Lrp5(-/-) mice and particularly evident in mice in which the more flexible fixation was used. Bone formation was more reduced in Col1a1-Krm2 than in Lrp5(-/-) mice, whereas osteoclast number was similarly increased in both genotypes in comparison with wild-type mice. Using microarray analysis we identified reduced expression of genes mainly involved in osteogenesis that seemed to be responsible for the observed stronger impairment of healing in Col1a1-Krm2 mice. In line with these findings, we detected decreased expression of sphingomyelin phosphodiesterase 3 (Smpd3) and less active beta-catenin in the calli of Col1a1-Krm2 mice. Since Krm2 seems to play a significant role in regulating bone formation during fracture healing, antagonizing KRM2 might be a therapeutic option to improve fracture healing under compromised conditions, such as osteoporosis.
In the adult skeleton, bone remodeling is required to replace damaged bone and functionally adapt bone mass and structure according to the mechanical requirements. It is regulated by multiple endocrine and paracrine factors, including hormones and growth factors, which interact in a coordinated manner. Because the response of bone to mechanical signals is dependent on functional estrogen receptor (ER) and Wnt/β-catenin signaling and is impaired in postmenopausal osteoporosis by estrogen deficiency, it is of paramount importance to elucidate the underlying mechanisms as a basis for the development of new strategies in the treatment of osteoporosis. The present study aimed to investigate the effectiveness of the activation of the ligand-dependent ER and the Wnt/β-catenin signal transduction pathways on mechanically induced bone formation using ovariectomized mice as a model of postmenopausal bone loss. We demonstrated that both pathways interact in the regulation of bone mass adaption in response to mechanical loading and that the activation of Wnt/β-catenin signaling considerably increased mechanically induced bone formation, whereas the effects of estrogen treatment strictly depended on the estrogen status in the mice.
1,25-dihydroxyvitamin D3 (1,25D3) was reported to induce premature organismal aging in fibroblast growth factor-23 (Fgf23) and klotho deficient mice, which is of main interest as 1,25D3 supplementation of its precursor cholecalciferol is used in basic osteoporosis treatment. We wanted to know if 1,25D3 is able to modulate aging processes on a cellular level in human mesenchymal stem cells (hMSC). Effects of 100 nM 1,25D3 on hMSC were analyzed by cell proliferation and apoptosis assay, beta-galactosidase staining, VDR and surface marker immunocytochemistry, RT-PCR of 1,25D3-responsive, quiescence-and replicative senescence-associated genes. 1,25D3 treatment significantly inhibited hMSC proliferation and apoptosis after 72 h and delayed the development of replicative senescence in long-term cultures according to beta-galactosidase staining and P16 expression. Cell morphology changed from a fibroblast like appearance to broad and rounded shapes. Long term treatment did not induce lineage commitment in terms of osteogenic pathways but maintained their clonogenic capacity, their surface marker characteristics (expression of CD73, CD90, CD105) and their multipotency to develop towards the chondrogenic, adipogenic and osteogenic pathways. In conclusion, 1,25D3 delays replicative senescence in primary hMSC while the pro-aging effects seen in mouse models might mainly be due to elevated systemic phosphate levels, which propagate organismal aging.